Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study

OBJECTIVES: Our aim was to compare outcomes of hospitalized adults with severe COVID-19 and cytokine storm treated with tocilizumab or baricitinib. METHODS: A prospective, investigational, real-world study was performed from April 2020 to April 2021 at our center. COVID-19 severity was classified by...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakatos, Botond, Szabó, Bálint Gergely, Bobek, Ilona, Kiss-Dala, Noémi, Gáspár, Zsófia, Riczu, Alexandra, Petrik, Borisz, Farkas, Balázs Ferenc, Sebestyén, Gabriella, Gopcsa, László, Bekő, Gabriella, Sinkó, János, Reményi, Péter, Szlávik, János, Mathiász, Dóra, Vályi-Nagy, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621622/
https://www.ncbi.nlm.nih.gov/pubmed/36328291
http://dx.doi.org/10.1016/j.ijid.2022.10.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621622/
https://www.ncbi.nlm.nih.gov/pubmed/36328291
http://dx.doi.org/10.1016/j.ijid.2022.10.037

Ejemplares similares